Em recrutamento
FASE
Número Europeu 2017-004417-42 (EudraCT); 2022-500255-24-00 (EU CT)
MK-3475-587/KEYNOTE-587
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
Detalhes
Destaques